LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CodeBreaK200 did not meet its secondary endpoint of OS; median OS was 10.6 months for sotorasib and 11.3 months for docetaxel (HR 1.01, 95% CI 0.77-1.33; p = 0.53).
“However, the study did not meet its secondary endpoint of OS. Median OS was 10.6 months (95% CI 8.9–14.0) for sotorasib and 11.3 months (9.0–14.9) for docetaxel (HR 1.01, 95% CI 0.77–1.33; p = 0.53).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [96]
The OS data in CodeBreaK200 are not yet mature and the study was underpowered to show OS differences.
“While the OS data are not yet mature and the study was underpowered to show OS differences, these results are disappointing and highlight the challenges with targeting KRAS.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [96]
CodeBreaK200 met its primary endpoint; PFS was 5.6 months with sotorasib and 4.5 months with docetaxel (HR 0.66, 95% CI 0.51-0.86; p = 0.002).
“The trial met its primary endpoint and PFS was 5.6 months (95% CI 4.3–7.8) with sotorasib and 4.5 months (95% CI 3.0–5.7) with docetaxel (HR 0.66, 95% CI 0.51–0.86; p = 0.002).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Still being checked.
Cited by
Sorted by citations
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 144 · see citing works
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 105 · see citing works
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 93 · see citing works
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Hattori, T., Maso, L., Araki, K. Y., Koide, A., Hayman, J., Akkapeddi, P., Bang, I., Neel, B. G., & Koide, S. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1074 · Cited by 72 · see citing works
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 57 · see citing works
Thummalapalli, R., Bernstein, E., Herzberg, B. O., Li, B. T., Iqbal, A. N., Preeshagul, I. R., Santini, F. C., Eng, J., Ladanyi, M., Yang, S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00030 · Cited by 43 · see citing works
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Lee, A. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00922-w · Cited by 39 · see citing works
Owen, D. H., Singh, N., Ismaila, N., Blanchard, E. M., Celano, P., Florez, N., Jain, D., Leighl, N. B., Mamdani, H. M., Masters, G. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.02124 · Cited by 32 · see citing works
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 31 · see citing works
Self-citationTargeting KRAS in Pancreatic Cancer
Cowzer, D., Zameer, M., Conroy, M. R., Kölch, W., & Duffy, A. G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111870 · Cited by 29 · see citing works
Manolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 27 · see citing works
Lamberti, G., Aizer, A. A., Ricciuti, B., Alessi, J. V., Pecci, F., Tseng, S.-C., Sholl, L. M., Nishino, M., & Awad, M. M. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00621 · Cited by 26 · see citing works
Desai, A. P., Rakshit, S., Bansal, R., Ashara, Y. P., Potter, A. L., Manochakian, R., Lou, Y., Zhao, Y., Ernani, V., Savvides, P., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100743 · Cited by 23 · see citing works
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 22 · see citing works
Frost, M. G., Jensen, K. J., Gotfredsen, D. R., Sørensen, A. M. S., Ankarfeldt, M. Z., Louie, K. S., Sroczynski, N., Jakobsen, E. H., Andersen, J. L., Jimenez‐Solem, E., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.021 · Cited by 17 · see citing works
Top advances of the year: Precision oncology
Desai, A. P., Reddy, N. K., & Subbiah, V. (2023) · Cancer · doi:10.1002/cncr.34743 · Cited by 14 · see citing works
Herzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 14 · see citing works
Olivier, T., Haslam, A., & Prasad, V. K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101591 · Cited by 13 · see citing works
Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022
Huang, Y., & Zhang, L. (2023) · Cancer Innovation · doi:10.1002/cai2.56 · Cited by 12 · see citing works
Current status of molecular diagnostics for lung cancer
Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 12 · see citing works
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 10 · see citing works
Noordhof, A. L., Swart, E. M., Damhuis, R. A. M., Hendriks, L. E. L., Kunst, P. W. A., Aarts, M. J., & van Geffen, W. H. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100543 · Cited by 10 · see citing works
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 9 · see citing works
Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
Wang, K., Leyba, A., & Hsu, R. C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00277 · Cited by 8 · see citing works
Knetki‐Wróblewska, M., Tabor, S., Płużański, A., Lewandowska, Z., Tysarowski, A., Pawlik, H., Kowalski, D. M., & Krzakowski, M. J. (2022) · Current Oncology · doi:10.3390/curroncol30010037 · Cited by 7 · see citing works
Chour, A., Basse, C., Lebossé, F., Bonté, P., Girard, N., & Duruisseaux, M. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107789 · Cited by 6 · see citing works
Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer
Möhrmann, L., Cuberi, A., Brückmann, S., Stasik, S., Heukamp, L. C., Bornhäuser, M., Glimm, H., & Folprecht, G. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00666 · Cited by 5 · see citing works
Targeted Therapy for Non–Small Cell Lung Cancer
Brea, E. J., & Rotow, J. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.009 · Cited by 3 · see citing works
Hamilton, G., Stickler, S., & Rath, B. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00178 · Cited by 3 · see citing works
Jiang, Y., Zhao, M., Liu, R., & Zheng, X. (2023) · Medicine · doi:10.1097/md.0000000000036387 · Cited by 3 · see citing works
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Karachaliou, A., Kotteas, E. A., Fiste, O., & Syrigos, K. (2024) · Cancers · doi:10.3390/cancers16081447 · Cited by 3 · see citing works
ESMO 2022 personal non-small lung cancer (NSCLC) highlights
Horvath, L., & Pall, G. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00887-0 · Cited by 2 · see citing works
Berchem, G., & Peters, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_3-1 · Cited by 1 · see citing works
Rolando, C., & Quagliata, L. (2022) · EMJ Oncology · doi:10.33590/emjoncol/10019771
Christopoulos, P. (2023) · Deutsches Ärzteblatt · doi:10.3238/personko.2023.03.03.02
Use of next-generation sequencing in daily routine practice
Płużański, A., Tysarowski, A., Kawecki, M., Kucharz, J., Winiarczyk, K., & Krzakowski, M. J. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0001
Elmarrachi, H., Andrif, M., & Ismaili, N. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100974
- Authors
- Johnson, M. L., de Langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S.-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y., & Paz-Ares, L.
- Affiliations
- Sarah Cannon (US)
- Oncology Hematology Care (US)
- Erasmus MC Cancer Institute (NL)
- Henry Dunant Hospital (GR)
- Kantonsspital Winterthur (CH)
- University Hospital Cologne (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Kyushu University (JP)
- Asan Medical Center (KR)
- Metropolitan Hospital (GR)
- Ospedale San Luigi Gonzaga (IT)
- Peter MacCallum Cancer Centre (AU)
- Amgen (United States) (US)
- Hospital Universitario 12 De Octubre (ES)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 33
- Pages
- S1417-S1418
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4297981973
- Cited by
- 39
- References
- 1
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 19 · 2022: 11
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, docetaxel, KRAS G12C mutation, non-small cell lung cancer, previously treated advanced NSCLC, oral targeted therapy, first-line therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
